Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan
- PMID: 11205460
- DOI: 10.1093/oxfordjournals.annonc.a010406
Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan
Abstract
Background: Women treated with tamoxifen for breast cancer are at increased risk of endometrial cancer. We conducted a retrospective cohort study to evaluate the risk of second primary cancers after adjuvant tamoxifen therapy for breast cancer in Japan.
Patients and methods: The subjects of the study were 6148 women who had been diagnosed with stage I, II, or IIIA unilateral primary breast cancer and had received surgical treatment during the period from January 1982 through December 1990 at nine institutions in Japan. The information on each patient was obtained from medical records or a prospectively compiled computer database at each institution.
Results: Of the 6148 women, 3588 (58.4%) were administered tamoxifen as an adjuvant treatment and 2560 (41.6%) were not administered. Median follow-up periods were 7.64 years for tamoxifen-treated patients and 8.10 years for non-tamoxifen-treated patients, respectively. The duration of tamoxifen treatment was mostly two years or less (80.7%), and few patients received tamoxifen for more than five years. The cumulative incidence rates of all second cancers at 10 years were 4.61% and 4.09% among tamoxifen-treated and non-tamoxifen-treated patients (P = 0.62), respectively, and the incidence rate ratio (IRR) for all second cancers was 1.06 (95% confidence interval (CI): 0.77-1.47) after adjustment of several covariates. The numbers of endometrial cancers was 9 and 3 among tamoxifen-treated and non-tamoxifen-treated patients, respectively, and the IRR was 2.37 (95% CI: 0.64-8.77, P = 0.20). Of the 12 patients who developed endometrial cancer, 4 died of cancer (for 3 of them, the cause of death was breast cancer), and the other 8 patients were alive as of March 1996. Stomach cancer was the most frequent second cancer and the IRR was 1.34 (95% CI: 0.76-2.38, P = 0.31). There was no substantial increase in any other type of gastrointestinal cancer such as colorectal and liver cancers among tamoxifen-treated patients.
Conclusions: The incidence and risk of second primary cancers associated with tamoxifen therapy is low. The potential benefit of adjuvant tamoxifen therapy in breast cancer patients outweighs the risk of second primary cancers for Japanese breast cancer patients.
Similar articles
-
Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group.J Natl Cancer Inst. 1995 May 3;87(9):645-51. doi: 10.1093/jnci/87.9.645. J Natl Cancer Inst. 1995. PMID: 7752269 Clinical Trial.
-
Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.J Natl Cancer Inst. 1994 Apr 6;86(7):527-37. doi: 10.1093/jnci/86.7.527. J Natl Cancer Inst. 1994. PMID: 8133536 Clinical Trial.
-
Endometrial and other primary cancers after tamoxifen treatment of breast cancer -- results of retrospective cohort study.Eur J Obstet Gynecol Reprod Biol. 2001 Mar;95(1):105-10. doi: 10.1016/s0301-2115(00)00376-6. Eur J Obstet Gynecol Reprod Biol. 2001. PMID: 11267730
-
Endometrial adenosarcoma with adjuvant tamoxifen therapy for primary breast carcinoma.Australas Radiol. 1998 May;42(2):157-8. doi: 10.1111/j.1440-1673.1998.tb00596.x. Australas Radiol. 1998. PMID: 9599835 Review. No abstract available.
-
Scientific review of tamoxifen. Overview from a medical oncologist.Semin Oncol. 1997 Feb;24(1 Suppl 1):S1-151-S1-7. Semin Oncol. 1997. PMID: 9045312 Review.
Cited by
-
Meta-analysis of vascular and neoplastic events associated with tamoxifen.J Gen Intern Med. 2003 Nov;18(11):937-47. doi: 10.1046/j.1525-1497.2003.20724.x. J Gen Intern Med. 2003. PMID: 14687281 Free PMC article.
-
Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States.Mol Cancer Ther. 2013 Oct;12(10):2261-72. doi: 10.1158/1535-7163.MCT-12-1134. Epub 2013 Aug 5. Mol Cancer Ther. 2013. PMID: 23918832 Free PMC article.
-
Other primary malignancies in breast cancer patients treated with breast conserving surgery and radiation therapy.Ann Surg Oncol. 2013 May;20(5):1514-21. doi: 10.1245/s10434-012-2774-8. Epub 2012 Dec 6. Ann Surg Oncol. 2013. PMID: 23224829 Free PMC article.
-
Cancer risk after exposure to treatments for ovulation induction.Am J Epidemiol. 2009 Feb 1;169(3):365-75. doi: 10.1093/aje/kwn318. Epub 2008 Nov 26. Am J Epidemiol. 2009. PMID: 19037008 Free PMC article.
-
Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis.Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):20-38. doi: 10.1158/1055-9965.EPI-11-0834. Epub 2011 Oct 25. Cancer Epidemiol Biomarkers Prev. 2012. PMID: 22028402 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical